|1.||McGovern, Karen: 6 articles (05/2014 - 06/2009)|
|2.||Kutok, Jeffery L: 2 articles (07/2015 - 01/2014)|
|3.||Campbell, Veronica T: 2 articles (05/2014 - 01/2014)|
|4.||Wunder, Jay S: 2 articles (05/2014 - 02/2014)|
|5.||Alman, Benjamin A: 2 articles (05/2014 - 02/2014)|
|6.||Proctor, Jennifer L: 2 articles (01/2014 - 01/2011)|
|7.||Read, Margaret A: 2 articles (01/2014 - 07/2009)|
|8.||Whitebread, Nigel: 2 articles (01/2014 - 06/2009)|
|9.||Jimeno, Antonio: 2 articles (06/2013 - 05/2013)|
|10.||Saif, Muhammad Wasif: 2 articles (03/2012 - 07/2011)|
05/15/2013 - "Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors."
02/15/2014 - "IPI-926 inhibited the Hedgehog signaling interactions between the tumor and the stroma and demonstrated antitumor efficacy in 1 of 2 ligand-dependent models. "
05/15/2013 - "Patients with solid tumors refractory to standard therapy were given IPI-926 once daily (QD) by mouth in 28-day cycles. "
01/01/2011 - "Chronic IPI-926 therapy for 21 days, however, inhibited Hh signaling in both mouse stromal and human tumor cells. "
01/01/2011 - "A single dose of IPI-926 inhibited mouse stromal Gli1 transcript levels at 24 hours with unchanged human intra-tumor Gli1 levels. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
07/01/2011 - "It appears that hedgehog inhibition with IPI-926 was well-tolerated and might be effective in treating pancreatic cancer when combined with gemcitabine. "
01/01/2010 - "Several Shh inhibitors have not succeeded in the clinic for unknown reasons, but clinical trials in BCC and pancreatic cancer with the promising Smo antagonists GDC-0449 and IPI-926 are currently underway."
|3.||Primary Myelofibrosis (Myelosclerosis)
07/01/2015 - "The clinical safety and efficacy of IPI-926 was evaluated in 14 patients with myelofibrosis in a phase II study. "
07/01/2015 - "The results did not support continued evaluation of IPI-926 as a monotherapy in myelofibrosis. "
07/01/2015 - "Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis."
07/23/2009 - "These studies led to the discovery of IPI-926 (compound 28), a novel semisynthetic cyclopamine analogue with substantially improved pharmaceutical properties and potency and a favorable pharmacokinetic profile relative to cyclopamine and compound 2. As a result, complete tumor regression was observed in a Hh-dependent medulloblastoma allograft model after daily oral administration of 40 mg/kg of compound 28."
|5.||Gastrointestinal Neoplasms (Gastrointestinal Cancer)
|1.||Homologous Transplantation (Allograft)
|3.||Heterologous Transplantation (Xenotransplantation)